Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease
- PMID: 28924974
- DOI: 10.1002/ajh.24908
Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease
Abstract
Delayed hemolytic transfusion reaction (DHTR) is a life-threatening complication of transfusion in sickle cell disease (SCD). The frequency of DHTR is underestimated because its symptoms mimic those of vaso-occlusive crisis and antibodies (Abs) are often not detectable. No predictive factors for identifying patients likely to develop DHTR have yet been defined. We conducted a prospective single-center observational study over 30 months in adult sickle cell patients. We included 694 transfusion episodes (TEs) in 311 patients, divided into occasional TEs (OTEs: 360) and chronic transfusion program (CTEs: 334). During follow-up, 15 cases of DHTR were recorded, exclusively after OTEs. DHTR incidence was 4.2% per OTE (95% CI [2.6; 6.9]) and 6.8% per patient during the 30 months of the study (95% CI [4.2; 11.3]). We studied 11 additional DHTR cases, to construct a predictive score for DHTR. The DHTR mortality is high, 3 (11.5%) of the 26 DHTR patients died. The variables retained in the multivariate model were history of DHTR, number of units previously transfused and immunization status before transfusion. The resulting DHTR-predictive score had an area under the ROC curve of 0.850 [95% CI: 0.780-0.930], a negative-predictive value of 98.4% and a positive-predictive value of 50%. We report in our study population, for the first time, the incidence of DHTR, and, its occurrence exclusively in occasionally transfused patients. We also describe a simple score for predicting DHTR in patients undergoing occasional transfusion, to facilitate the management of blood transfusion in SCD patients.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease.Br J Haematol. 2022 Feb;196(3):769-776. doi: 10.1111/bjh.17875. Epub 2021 Oct 10. Br J Haematol. 2022. PMID: 34632580
-
Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.Pediatrics. 2003 Jun;111(6 Pt 1):e661-5. doi: 10.1542/peds.111.6.e661. Pediatrics. 2003. PMID: 12777582
-
How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.Br J Haematol. 2015 Sep;170(6):745-56. doi: 10.1111/bjh.13494. Epub 2015 May 13. Br J Haematol. 2015. PMID: 25967919 Review.
-
Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.Am J Hematol. 2016 Oct;91(10):989-94. doi: 10.1002/ajh.24460. Epub 2016 Jul 14. Am J Hematol. 2016. PMID: 27348613
-
Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).Transfus Clin Biol. 2019 May;26(2):102-108. doi: 10.1016/j.tracli.2019.02.006. Epub 2019 Feb 22. Transfus Clin Biol. 2019. PMID: 30885514 Review.
Cited by
-
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.Pediatr Blood Cancer. 2024 Aug;71(8):e31061. doi: 10.1002/pbc.31061. Epub 2024 Jun 5. Pediatr Blood Cancer. 2024. PMID: 38840429 Free PMC article.
-
Delayed hemolytic transfusion reaction in children with sickle cell disease: first 5-year retrospective study in mainland France.Haematologica. 2023 Mar 1;108(3):889-894. doi: 10.3324/haematol.2022.281050. Haematologica. 2023. PMID: 36325889 Free PMC article. No abstract available.
-
Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: A Case Series.Am J Case Rep. 2022 Jan 5;23:e934681. doi: 10.12659/AJCR.934681. Am J Case Rep. 2022. PMID: 34983921 Free PMC article.
-
Red cell alloimmunization is associated with increased health care costs, longer hospitalizations, and higher mortality.Blood Adv. 2022 Oct 25;6(20):5655-5658. doi: 10.1182/bloodadvances.2022006982. Blood Adv. 2022. PMID: 35939787 Free PMC article. No abstract available.
-
Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88.J Immunol. 2022 Feb 15;208(4):991-997. doi: 10.4049/jimmunol.2100784. Epub 2022 Jan 17. J Immunol. 2022. PMID: 35039331 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical